Establishment of Liquid Biopsy Platforms from longitudinal medulloblastoma patients

The CBTN samples will greatly expand our ability to validate and establish liquid biopsy platforms for the monitoring of longitudinal medulloblastoma patients and recurrently medulloblastoma patients with longitudinal samples. For many medulloblastoma patients’ serial plasma and cerebral spinal fluid samples are collected. Currently, in our biobank we have 30 medulloblastoma patients with 2 or more serial cerebral spinal fluid or plasma samples. Only 12 of those patients are recurrent, with only 6 having serial samples. The addition of CBTN samples to our testing will greatly expand the impact and utility of these platforms. Our team aims to develop this resource (while also including other pediatric CNS tumor types) and make it globally accessible to both clinicians and researchers. All data will be available to colleagues and collaborators.